CenterWatch announced a new service designed to assist biopharmaceutical companies and contract research organizations (CROs) in identifying and engaging investigative sites worldwide to conduct phase I through IV clinical trials.
Over the past several years, clinical research sponsors have become increasingly interested in recruiting skilled and active investigators from a larger and more diverse number of global regions. During this same period, the number of investigative sites exiting the clinical research enterprise has grown, as sites find it increasingly difficult to secure study grants. The new CenterWatch ‘Grant Notification Service’ is designed to match clinical research sponsors with currently active, experienced investigative sites and to provide an effective study grant generation tool for research professionals.
The service will be largely automated through the CenterWatch web site at www.centerwatch.com/trialwatch_signup and free of charge to use. By the end of September 2010, CenterWatch anticipates having 25,000 active global investigative sites registered on the service. In addition, CenterWatch anticipates handling three to five unique requests weekly from sponsor and CRO companies. Each specific request will generate a list of selected investigative sites to be contacted by the sponsor or CRO originating the request.
“We’re very pleased to be offering a new web-based service to the global investigative site community,” said Joan Chambers, CenterWatch Chief Operating Officer. “Our company has a long history of offering sites the opportunity to identify and secure study grants through our publications. We’re also excited to be providing sponsors and CROs with a quick and efficient way to identify and to ultimately contact viable investigative sites worldwide.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.